AI assistant
UroGen Pharma Ltd. — Director's Dealing 2020
Feb 18, 2020
32312_dirs_2020-02-18_04d9ad97-66e0-4273-a30b-3ee4f66366ea.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2020-02-14
Reporting Person: Mullennix Stephen (Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-02-14 | Ordinary Shares | M | 1759 | — | Acquired | 10424 | Direct |
| 2020-02-14 | Ordinary Shares | S | 612 | $28.04 | Disposed | 9812 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-02-14 | Restricted Stock Units | $ | M | 1759 | Disposed | Ordinary Shares (1759) | Direct |
Footnotes
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3: The reporting person was granted restricted stock units ("RSUs") on March 7, 2018, June 4, 2018 and October 28, 2018 representing 21,107 ordinary shares in the aggregate. 1/3rd of the RSUs vested on February 14, 2019, with the balance vesting in equal quarterly installments thereafter over a period of two years.